Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02504463 · ClinicalTrials.gov registry record · Phase 1

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers

A Phase 1 study, sponsored by Alkermes.

Completed
Registry status
Phase 1
Development phase
10
Enrollment target

NCT02504463: Completed Phase 1 study, sponsored by Alkermes.

NCT02504463 is a Phase 1 study that has completed, run by Alkermes. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02504463, a Phase 1 study, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 1
Development phase
10 participants
Enrollment target

Study Summary

This study will determine the pharmacokinetics (PK) of \[14c\]-samidorphan in healthy male volunteers.

Primary Outcome

Area under the concentration time curve of total radioactivity from time 0 to last observed concentration in blood and plasma

Interventions

  • DRUG Samidorphan IV
  • DRUG [14c]-Samidorphan sublingual
  • DRUG [14c]-Samidorphan oral

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-06
Est. Completion 2015-09
Phase Phase 1
Alkermes

66 total trials

What the finished NCT02504463 record still lists

NCT02504463 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 3 interventions - of which Samidorphan IV is the first listed.

NCT02504463 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02504463 about?

NCT02504463 is a clinical study titled "A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers". This study will determine the pharmacokinetics (PK) of \[14c\]-samidorphan in healthy male volunteers.

What is the current status of trial NCT02504463?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2015-06. Estimated completion is 2015-09.

What interventions are being tested in trial NCT02504463?

The interventions under investigation include: Samidorphan IV (DRUG), [14c]-Samidorphan sublingual (DRUG), [14c]-Samidorphan oral (DRUG).

Who is sponsoring clinical trial NCT02504463?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02504463's enrollment target sits among peer trials

10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02504463, the US trial registry maintained by the National Library of Medicine. NCT02504463 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.